High-dose cytotoxic chemotherapy followed by autologous haematopoietic stem cell transplantation (ASCT) is extensively used for the treatment of many haematopoietic, as well as several epithelial cancers. Disease relapse may be the result of tumour contamination within autograft as evidenced by gene marking studies. The multiple purging strategies that have been described to date have not proven effective in most ASCT settings. This review addresses the possibility of using oncolytic viruses as a novel purging strategy. DNA viruses such as genetically engineered adenoviral vectors have widely been used to deliver either a prodrug-activating enzyme or express wild-type p53 selectively in tumour cells in ex vivo purging protocols. In addition, conditionally replicating adenoviruses that selectively replicate in tumour cells and herpes simplex virus type 1 are other DNA viruses that have been tested as ex vivo purging agents under laboratory conditions. Vesicular stomatitis virus (VSV) and reovirus are naturally occurring RNA viruses that appear to hold promise as purging agents under ex vivo and in vivo settings. Preclinical data demonstrate reovirus's purging potential against breast, monocytic and myeloma cell lines as well as patient-derived tumours of diffuse large B-cell lymphoma, chronic lymphocytic leukaemia, Waldenstrom macroglobulinemia and small lymphocytic lymphoma. In addition, VSV has shown effective killing of leukaemic cell lines and multiple myeloma patient specimens. Given the increasing interest in the utilization of viruses as purging agents, the following review provides a timely summary of the potential and the challenges of oncolytic viruses as purging modalities during ASCT.
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Autologous haematopoietic stem cell transplantation
Stem cell rescue following high-dose bone marrow ablative therapy is considered curative and has gained extensive application as a therapeutic modality in several haematological malignancies as well as in a few solid tumours. [1] [2] [3] [4] [5] [6] [7] Owing to the low treatment-related mortality rates (o3%) and the absence of a need for a suitable donor, autologous haematopoietic stem cell transplantation (ASCT) now surpass the number of allotransplantations conducted worldwide. [8] [9] [10] Despite the significant increase in ASCT, disease relapse remains a primary cause of death following transplantation.
11 Therapy-resistant systemic disease and occult clonogenic tumour cells within the autograft are two possible contributors of relapse following high-dose chemotherapy and ASCT. Autograft contamination has been confirmed through flow cytometry, immunohistochemistry and molecular diagnostic methodologies for a variety of tumour types as depicted in Table 1. 12-29 Further, evidence supported by gene marking studies indicates relapse following high-dose ablative therapy and ASCT may be due to these contaminating cancer cells within the autograft. [30] [31] [32] It has been estimated that 30% of all autografts may be contaminated with tumour cells; likely an underestimation because of previous limitations in methodologies for minimal residual disease (MRD) detection.
The contribution to disease relapse by these contaminating tumour cells may depend on both the number of contaminating tumour cells within the graft as well as biology of the individual tumour. 33 International Bone Marrow Transplant Registry (IBMRT) data suggest that relapse rates after ASCT for lymphoma may be improved by 15% with purging; however, this was based on nonrandomized comparisons and thus subject to considerable bias. 34 While controversy still exists as 'to purge' or 'not to purge' an autograft, several studies suggest that graft manipulation is of clinical benefit. [35] [36] [37] [38] These findings have subsequently fostered a variety of purging strategies involving in vivo and/or ex vivo purging. Ideally, the purging procedure should preferentially destroy contaminating tumour cells while preserving the number and function of normal haematopoietic stem cells and be technically feasible for routine clinical practice.
Ex vivo purging strategies
Non-viral-based purging systems In an ex vivo setting, several purging strategies such as, tumour targeting with monoclonal antibodies (MoAbs) and/or linked to toxins 39, 40 positive haematopoietic stem AFP mRNA detected in all patients after 1st and 2nd rounds of (IC) but not detected in 3 4 samples after 3rd round of IC Kasahara et al. cell (CD34 þ ) selection 41, 42 ex vivo chemotherapy, 43 photodynamic purging processes 44, 45 and receptor-targeted ligand toxins such as Shiga-like toxin-1, a ribosome-inactivating protein with receptor expression in several tumour cell lines but not in CD34 þ cells 46, 47 have been tested to minimize tumour cell contamination in autografts and reduce post transplant relapse. While the efficacy of the latter two purging methods has yet to be tested in clinical trials, the other methods, for a number of reasons have not been universally adopted into the clinical setting for depleting autografts of tumour cells. For example, CD34 þ enrichment results in about 50% loss of the processed CD34 þ cells and a 2-3 log depletion of T and B cells. 48 In addition to removing T and B cells, this method could also lead to the loss of monocytes, natural-killer cells and T-helper cells thereby delaying immune recovery. 49 Although antibodybased purging methods are not associated with significant CD34 þ cell loss they are technically demanding and are associated with high cost. Chemotherapy-based purging techniques are associated with considerable loss of stem cells and committed progenitors, thereby delaying bone marrow engraftment, especially platelet recovery. 50, 51 Thus, owing to the lack of presently available efficient purging methodologies other purging strategies such as oncolytic viral-based purging methods are needed.
Viral-based purging strategies
With a more comprehensive understanding of the molecular basis of tumorigenesis and viral genomics the exploitation of certain viruses as anticancer agents has garnered significant interest over the past decade. As such, their use as a purging strategy for a number of malignancies has also been exploited. A virus with intrinsic or engineered tumour selectivity that kills tumour cells is termed as an 'oncolytic viral vector', whereas non-lytic vectors express transgenes that generate anticancer effects. 52 Oncolytic viruses have several advantages over conventional anticancer therapeutics. Primarily, their ability to self-replicate within the tumour cell and disseminate and target surrounding cancer cells is one such unique property. With the use of recombinant DNA technology, the scope for creating novel 'designer viruses' appears to be limitless and therefore very promising. Viruses genetically engineered to express toxic suicidal genes, immune stimulatory products within the tumour and/or tumour-specific inflammatory responses, are attractive candidates to be used as either ex vivo or in vivo purging agents. Table 2 summarizes the naturally occurring viruses or genetically engineered viral vectors that have been evaluated as purging agents over the past decade. [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] A large number of virally mediated approaches have been utilized ex vivo to purge contaminating tumour cells from autografts that report purging efficacies ranging from 2 to 6 log depletions of tumour cells (Table 2 ). Direct comparison of the purging efficacy of one purging strategy to another is difficult as both the methodology for MRD detection varies considerably between studies, that is, tumour cell outgrowth in methyl cellulose versus culture media; flow cytometry versus PCR (reverse transcriptase-PCR versus quantitative PCR) detection techniques. The best experimental method of documenting purging efficacy is the lack of disease relapse in transplanted animal models and the evidence of in vivo stem cell repopulating ability post ex vivo purging. There are several potential candidate viruses that have been used in preclinical purging studies. The advantages and disadvantages as well as potential limitations of the common viruses that have been investigated as purging agents are given in Table 3 .
Adenovirus. The majority of virally based purging methods involve attenuated non-replicative viral vectors, such as adenoviral vectors, that have been engineered to deliver either a prodrug-activating enzyme or express wild-type (WT) p53 selectively in tumour cells (Table 2 ). Adenoviruses (Ad) are non-enveloped DNA viruses, and WT Ad may cause subclinical infections of the upper respiratory tract. The preferential tumour targeting of Ad has been exploited in several ex vivo purging protocols involving breast, myeloma and neuroblastoma. [53] [54] [55] [56] [57] [58] 60, 61, 64, 65 The tumour cell selectivity of Ad is explained by the presence of the coxsackie Ad receptor on tumour cells in association with the expression of a v b 5 or a v b 3 integrins required for internalization of these virions into the tumour cell. 53 In contrast, Ad infection of haematopoietic stem cells has been shown to occur at a significantly lower frequency. 53, 58, 69 Ad vectors carrying transgenes appear to be 4000-fold less effective in transducing CD34 þ cells than tumour cells 53, 54, 70 and thus represent a very significant therapeutic window.
Ad as prodrug-activating enzyme delivery systems. Prodrug-activating enzymes transform prodrugs into active/ toxic metabolites. Prodrugs are usually inert over a wide range of doses in the absence of activating enzymes. Prodrug-activating enzyme delivery via viral transgenes appears to be an attractive method of tumour purging because of the significant bystander effect, mediating toxicity to neighbouring non-infected cancer cells. There are three prodrug-activating enzymes commonly used in the purging protocols; herpes simplex virus (HSV) thymidine kinase, which phosphorylates the anti-viral agent ganciclovir, Escherichia coli cytosine deaminase (CD), which converts the anti-fungal agent 5-fluorocytosine into the chemotherapeutic agent 5-flurouracil and lastly, rabbit carboxyl esterase (RCE) that activates the prodrug CP-T11. While these agents have successfully purged breast, myeloma and neuroblastoma cancer cell lines with little effect on stem cells, the only investigation involving ex vivo human cancer specimens has been neuroblastoma with RCE. 65 There are only three studies that have shown encouraging results of CD or RCE purging in mouse models that confirm stem cell engraftment and absence of relapse post purging (Table 1) . 55, 64, 65 Garcia-Sanchez et al. 55 have reported the effects of CD on mouse stem cell reconstitution. In this study, marrow cells collected from 5-FU-treated male donor mice were incubated with Ad-CD and exposed to 5-FC either for 5 days in vitro before transplantation or for 14 days in vivo immediately after transplantation in female lethally irradiated Balb/C mice. No significant decreases in the marrow reconstituting capability of male marrow cells, as measured by their persistence for up to 6 months in female recipients, were found. More recently, Lillo et al. 64 have demonstrated efficient and non-toxic Ad-CD purging of breast cancer utilizing non-obese diabetic/severe combined immune deficiency (NOD/SCID) immunosuppressed mouse models. Ad-CD purged or non-purged admixtures of human CD34 þ /breast cancer cells injected intravenously to NOD/SCID mice showed no significant differences in haematopoietic engraftment kinetics as well as the quantity or quality of human haematopoietic cell engraftment. Moreover, improvements in overall survival were observed in favour of the animals that received the purged product. Similarly, Wagner et al. 65 have demonstrated the efficacy and lack of toxicity of RCE purging of neuroblastoma in NOD/SCID mice. Mice that received purged cell preparations survived without evidence of disease for more than a year, whereas recipients of unpurged cells developed disseminated disease requiring euthanasia. No differences in CD34 þ repopulating ability were seen between purged and unpurged groups. These preclinical studies lend support for the translation of these findings to clinical settings. The assessment of the sensitivity of CD to ex vivo patient tumours has not currently been investigated and would be a prerequisite before they are moved into clinical trials.
Ad as p53 delivery systems. The fact that a majority of human malignancies harbour p53 mutations 71 is an attractive target for the development of Ad vectors containing WT p53 transgenes 54, 58, 61 as overexpression of WT p53 leads to tumour cell death via apoptosis. 72, 73 Three reports have described the feasibility of purging breast cancer cells by the delivery of WT p53 through Ad vectors (Table 1) . 54, 58, 61 The non-toxic nature of Ad-p53 on stem cell repopulating ability in NOD/SCID mice has been demonstrated by Hirai et al. 61 As shown by this group this method leads to a 2-4 log improvement in tumour purging in comparison to conventional breast purging strategies such as CD34 þ selection. Further advantages of this method are the absence of additional graft manipulation steps as in the prodrug purging methods where incubation of the graft or injection of recipients with the prodrug is mandatory post viral treatment.
Conditionally replicating Ad. Unlike adult tumours, neuroblastoma and Ewing's sarcoma appear to have fewer p53 mutations 74 and these malignancies tend to have less cell-to-cell contacts resulting in reduced bystander effects. 75 Therefore, Adachi et al. 63 have tested a conditionally replicating adenovirus harbouring a midkine (a growth differentiating factor) promoter (AdMKE1) that selectively infects tumour cells expressing midkine. Although admixed cells were not tested for purging potential, this study demonstrates that AdMKE1 could kill tumour cells and not harm CD34 þ cells, suggesting the possible use of this virus as a prospective purging agent for these malignancies.
Herpes simplex virus type 1. Herpes simplex virus type 1 (HSV-1/G207) is another oncolytic double-stranded enveloped DNA virus. Recombinant HSV-1 is made nonneurovirulent through deletions in the gamma 34.5 loci. Additional mutations in the ICP6 gene (a gene that encodes ribonucleotide reductase) further impair the ability of HSV-1 mutants to replicate in normal cells thus enhancing tumour selectivity. Wu et al. 62 have shown that breast cancer cell lines could be successfully purged ex vivo with HSV-1 with little effect on the clonogenic capacity of bone marrow stem cells. However, the effects of HSV-1 on ex vivo patient tumours and in vivo stem cell repopulating ability post HSV-1 purging have not been reported.
Vesicular stomatitis virus. The ability of RNA viruses to opportunistically utilize tumour cell defects for their replication has also been tested in the context of ex vivo tumour cell purging (Table 1) . 59, [66] [67] [68] Vesicular stomatitis virus (VSV) is a (À) strand enveloped RNA virus that has a broad host range with abilities to cause vesicular lesions. Although VSV infection of farm animals is common 76 the incidence of human infections are rare 77 and usually benign. 78 Naturally occurring VSV is exquisitely sensitive 59 Stojdl et al. 59 have demonstrated successful purging of acute meylogenous leukaemia (AML) cell line OCI/AML3 with WT VSV. OCI/AML3 cells cocultured with normal bone marrow cells at 10% tumour burden and in the presence of VSV showed complete ablation of tumour and sparing of bone marrow progenitors. 59 More recently, Lichty et al. 67 have shown several leukaemic cell lines and multiple myeloma ex vivo patient specimens to be exquisitely sensitive to VSV variants AV1, AV2 and heat resistant VSV. 67 In addition, this group also demonstrated that leukaemic cell lines could be purged successfully with these VSV variants with minimal effect on colony-forming ability of stem cells, suggesting potential use of these VSV mutants as purging agents. 67 To date, in vivo testing of the ex vivo purging efficacy of these VSV variants has not been undertaken.
Reovirus. A second potential virus, reovirus is a common environmental non-enveloped double-stranded RNA virus that causes mild infections of the upper respiratory and gastrointestinal tract of humans. Clinically, this virus is considered insignificant because reovirus infections are generally asymptomatic. 79 The virus infects cells with an aberrant Ras signalling pathway or downstream elements of this pathway for its replication. 80 Given the prevalence of Ras activity in human tumours, reovirus's oncolytic nature has been demonstrated against myriad neoplasms in vitro, in vivo and in ex vivo systems by our group (Reviewed by Norman and Lee
81
). Reovirus's selective tumour targeting ability, in vivo replicative capacity and its nontoxic nature towards haematopoietic stem cells makes it an attractive candidate to be used in purging protocols.
Reovirus effects on haematopoietic stem cells and its purging ability of myriad haematological malignancies and solid tumours have been studied comprehensively in our laboratory. 66, 68 We have found no adverse effects of reovirus on positively selected (CD34 þ ) stem cells that have been exposed to reovirus in culture medium for 5 days. In addition, these stem cells preserved their clonogenic potential as revealed by long-term colony-forming assays in methyl cellulose. 66 Utilizing metabolic labelling methodology, we have also confirmed that reovirus does not replicate in haematopoietic progenitor cells even after granulocyte colony-stimulating factor stimulation. 66 Together, these in vitro findings have implied that reovirus could purge autografts without affecting the number and function of stem cells.
Using an ex vivo purging model system, we have also demonstrated that apheresis product contaminated with 1% tumour burden (with U937 monocytic or RPMI 8226 myeloma cell lines) could be successfully purged by reovirus within 3 days. 66 Tumour-purging efficacy of these experiments were analysed by flow cytometry and tumour regrowth assays. Further, spiking apheresis products (1-10%) with cells of primary patient specimens of B-cell chronic lymphocytic leukaemia (B-CLL), diffuse large Bcell lymphoma, small cell lymphocytic lymphoma (SLL) or Waldenstrom macroglobulinemia and purging with reovirus resulted in successful elimination of malignant cells as revealed by flow cytometric analysis. All these malignancies are diseases for which autotransplantation is performed at present and this highlights the potential utility of reovirus as an ex vivo purging agent in a clinical setting.
Reovirus's purging potential has not only been studied in haematological malignancies but also recently in solid tumours such as breast cancer. 68 Formerly, our group and others have demonstrated that breast tumour micrometastases found in patients' apheresis product predict shorter progression-free survival and overall survival. These findings imply that either the contaminating tumour cells within the apheresis product reflect a higher systemic disease burden and/or that reinfused contaminating tumour cells contribute to relapse. The ex vivo breast purging model utilized in our study indicated the possibility of achieving complete purging up to 1% tumour burden. The tumour burden encountered in a clinical setting is usually o0.01% and this falls well within the range of purging efficacy seen in our experiments. 82 Ongoing experimentation aims at quantitating reovirus purging efficacy and human stem cell repopulating ability in vivo, utilizing a murine transplant model system. The aim of these purging experiments is to generate preclinical data that will eventually be translated into a clinical trial.
In vivo purging strategies
Non-viral purging strategies Conventional in vivo purging methods aim at improving systemic control of malignant disease as well as alteration of the kinetics of tumour cell mobilization. Non-viral based in vivo purging methods involve treatment of patients with systemic chemotherapy and/or MoAbs with the hope of reducing the systemic circulating tumour cell burden. Intensive chemotherapy regimens given to chronic myelogenous leukaemia (CML) patients have shown improved outcome in 22 out of 30 patients tested for philadelphia chromosome in their haematopoietic progenitor cell products. 83 Similarly, Rituximab, a MoAb directed against the B-cell-surface antigen CD20 has shown promise in B-cell non-Hodgkin's lymphoma (NHL) patients 42, 84 and, Rituximab, in combination with chemotherapy, has shown molecular remission of detectable bcl-2-positive NHL patients. 85 Imatinib, the small molecular tyrosine kinase inhibitor directed at the ATP binding pocket of bcr-abl fusion protein, has shown promise as an in vivo purging agent in a phase II trial involving CML patients. 86 Although these clinical trials have shown promise for in vivo purging, more rigorous testing of these purging agents in randomized trials awaits their justification before being adopted in standard clinical practice.
Viral purging strategies
As in conventional in vivo purging, replicating oncolytic viruses are attractive agents to control systemic malignancy and may well be able to reduce tumour contamination within stem cell mobilization products. While it is too early to speculate about the benefits of in vivo viral purging, it is apparent that RNA viruses have more desirable features than Ad or HSV. For example, reovirus fulfils many of the ideal attributes of an oncolytic viral therapeutic; namely it exploits a common pathway unique to transformed cells, is genomically stable, easily manufactured and has minimal toxicity. Systemic reovirus therapy in combination with immunosuppressants has shown promising results in animal models. 87 To date, there have been upwards of 60 patients treated with clinical grade reovirus (REOLYSIN) intratumourally, intracerebrally and intravenously during early clinical testing in cancer patients with resultant minimal toxicity attributed to REOLYSIN exemplifying the broad therapeutic window of this viral agent. These studies are to be published in 2007. However, preliminary abstract data suggest that maximum tolerated dose has not been reached for systemic (intravenous) or for intracerebral injections for the treatment of advanced malignancies. 88, 89 In the latter study, evidence of viral replication in tumour was observed with resultant tumour necrosis. 89 VSV is also of interest as an in vivo purging agent. It has the advantage of a short reproductive cycle that results in high viral titres within the tumour microenvironment and is oncolytic to many cancers that ASCT is indicated for. A potential drawback of using in vivo viruses as both an in vivo purging and systemic treatment is the resultant stimulation of the immune system and subsequent development of neutralizing antibodies. Preliminary investigations involving reovirus suggest that this immune response may be harnessed by use of dentritic cells as antigenpresenting cells to present virus in the context of tumour antigens to immune effectors before high-dose chemotherapy and resultant virally directed tumour immunotherapy.
Future directions
To date, apart from positive CD34 þ cell selection, very little clinical manipulation to rid tumour cells from the autograft takes place routinely during ASCT. The majority of the existing purging methodologies are either inefficient, toxic, physically/functionally stem cell depleting or are too laborious to be considered applicable to routine practice. Further, there are many haematological cancers such as CLL that are not routinely considered for ASCT because of the likely tumour cell load within the autograft. The utilization of reovirus viral purging is attractive because of a number of reasons namely; efficacy, lack of effect on stem cell number/function, tumour cell selectivity eliminating the need to clear residual virus from the autograft before reinfusion, minimal autograft manipulation and relative ease of manufacturing and storage.
To our knowledge, there has been no viral purging methodology translated into human clinical trials to date. This is partly due to the relatively recent systemic human testing of these biologicals in the clinic and the lack of clinical data in immunocompromised patients; however, as viral safety profiles are increasingly well understood especially in immunosuppressed hosts, oncolytic viruses, including reovirus, represent a very attractive purging strategy to decrease tumour recurrence post ASCT. Regulatory authorities will likely require systemic safety data as well as viral shedding studies in immunosuppressed non-human primates before approval of viral purging human clinical trials or alternatively evidence that virus present in the autograft post purging and freeze-thaw procedure is at a trivial concentration that poses less risk to a myelosuppressed patient. The knowledge that the majority of adults have already been exposed to reovirus in the past as evidenced by seroconversion and the possibility of passive immunization with reovirus anti-sera tempers this concern of potential toxicity.
We predict that in the next several years several of these viruses will be in clinical trials as potential purging agents for selected cancers and may well represent a significant therapeutic gain for current ASCT indications and may, in fact, expand the number of cancers for which ASCT may be an applicable therapeutic option.
